文献速递儿童血液肿瘤与免疫

MRD指导的危险度分层在不同亚型儿童B-ALL中的价值

[The value of minimal residual disease-guided risk stratification in different subtypes of pediatric B-cell acute lymphoblastic leukemia].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2026-01-01

该回顾性队列纳入666例初诊B-ALL患儿,按ETV6::RUNX1阳性、超二倍体及NENH-B-ALL分组,评估MRD指导危险度调整的价值。ETV6::RUNX1阳性和超二倍体组中危患儿经MRD调整后生存率与低危相当,而NENH-B-ALL组MRD虽可分层但治疗调整未能消除预后差异。

要点

  • ETV6::RUNX1阳性或超二倍体B-ALL中,MRD指导的危险度调整使中危患儿EFS与低危相当。
  • NENH-B-ALL中MRD可区分低、中、高危,但治疗强度调整未消除预后差异。
  • 年龄≥10岁、初诊WBC≥50×10⁹/L、d15 MRD≥0.1%、d29 MRD≥0.01%及NENH-B-ALL为独立不良预后因素。

核心结论

  • ETV6::RUNX1阳性或超二倍体患儿经MRD指导危险度调整后,中危组生存率与低危组相当。
  • NENH-B-ALL中MRD可有效划分低、中、高危,但治疗调整未能消除预后差异。

研究设计与样本

  • 回顾性队列研究,纳入浙江大学医学院附属儿童医院2018年10月至2023年6月666例初诊B-ALL患儿,采用ZJCH-ALL-2019方案进行危险度分层和治疗。
  • 按遗传学特征分为ETV6::RUNX1融合基因阳性组168例(25.2%)、超二倍体组199例(29.9%)和NENH-B-ALL组293例(44.0%),另有6例为超二倍体合并ETV6::RUNX1阳性。

主要发现

  • 666例患儿5年OS为(95.9±0.8)%,5年EFS为(92.1±1.2)%。
  • ETV6::RUNX1阳性和超二倍体组EFS优于NENH-B-ALL组[(97.6±1.2)%、(96.5±1.4)%比(85.6±2.4)%,P<0.001]。
  • ETV6::RUNX1阳性组低、中、高危5年EFS分别为100%、(98.5±1.5)%和(80.0±10.7)%(P<0.001)。
  • 超二倍体组低、中、高危5年EFS分别为(96.7±1.9)%、100%和(87.7±6.7)%(P<0.001)。
  • NENH-B-ALL组低、中、高危5年EFS分别为(97.2±1.9)%、(85.8±3.6)%和(74.4±5.4)%(P<0.001)。

关键数值与推荐

  • 153例(23.0%)根据第15天MRD水平、5例(0.8%)根据第29天MRD水平进行了危险度调整。
  • 多因素分析显示年龄≥10岁(HR=3.37,95%CI 1.81~6.27)、初诊白细胞计数≥50×10⁹/L(HR=2.31,95%CI 1.24~4.32)、第15天MRD≥0.1%(HR=1.88,95%CI 1.01~3.49)、第29天MRD≥0.01%(HR=2.72,95%CI 1.19~6.21)及NENH-B-ALL(HR=1.66,95%CI 1.16~2.39)均为独立不良预后因素(均P<0.05)。

临床怎么用

  • 对ETV6::RUNX1阳性或超二倍体B-ALL患儿,可依据第15天和第29天MRD水平调整危险度,使中危患儿获得与低危相当的生存。
  • 对NENH-B-ALL患儿,MRD可识别低、中、高危层次,但仅靠治疗强度调整不足以消除预后差异,需探索其他干预策略。

局限性

  • 本研究为单中心回顾性队列研究。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the clinical value of minimal residual disease (MRD)-guided risk stratification in different subtypes of pediatric B-cell acute lymphoblastic leukemia (B-ALL). Methods: In this retrospective cohort study, a total of 666 newly diagnosed B-ALL children admitted to the Children's Hospital, Zhejiang University School of Medicine between October 2018 and June 2023 were enrolled. Risk stratification (low, intermediate, and high risk) and treatment were conducted according to the Zhejiang Children's Hospital acute lymphoblastic leukemia (ZJCH-ALL)-2019 protocol. Based on the cytogenetic and molecular biological characteristics of leukemia cells, patients were categorized into three groups: ETV6::RUNX1 fusion gene-positive group, hyperdiploid group, and non-ETV6::RUNX1 and non-hyperdiploid B-ALL (NENH-B-ALL) group. The adjustments in risk stratification based on MRD levels across these groups were analyzed. The value of MRD-based risk adjustment strategies in different B-ALL subgroups was assessed using Kaplan-Meier survival analysis and the Cox proportional hazards model. Results: Among the 666 patients, there were 379 males and 287 females, with the age of onset 4.7 (3.2, 7.6) years. The ETV6::RUNX1-positive, hyperdiploid, and NENH-B-ALL groups comprised 168 (25.2%), 199 (29.9%) and 293 (44.0%) patients, respectively; additionally, 6 patients exhibited both hyperdiploidy and ETV6::RUNX1 positivity. Risk stratification was adjusted based on MRD levels on day 15 and day 29 in 153 (23.0%) and 5 (0.8%) patients, respectively. The 5-year overall survival (OS) and event-free survival (EFS) rates for all 666 patients were (95.9±0.8)% and (92.1±1.2)%, respectively. Notably, EFS was significantly superior in the ETV6::RUNX1-positive and hyperdiploid groups compared to NENH-B-ALL group ((97.6±1.2)% and (96.5±1.4)% vs. (85.6±2.4)%, P<0.001). In the ETV6::RUNX1-positive group, the 5-year EFS rates for the low, intermediate, and high-risk groups were 100%, (98.5±1.5)%, and (80.0±10.7)%, respectively (P<0.001). In the hyperdiploid group, the 5-year EFS rates were (96.7±1.9)%, 100%, and (87.7±6.7)% (P<0.001). In the NENH-B-ALL group, the 5-year EFS rates were (97.2±1.9)%, (85.8±3.6)%, and (74.4±5.4)% (P<0.001). Multivariate analysis identified age ≥10 years (HR=3.37, 95%CI 1.81-6.27), initial white blood cell count ≥50×109/L (HR=2.31, 95%CI 1.24-4.32), MRD ≥0.1% on day 15 (HR=1.88, 95%CI 1.01-3.49), MRD ≥0.01% on day 29 (HR=2.72, 95%CI 1.19-6.21), and NENH-B-ALL subtypes (HR=1.66, 95%CI 1.16-2.39) as independent adverse prognostic factors (all P<0.05). Conclusions: In patients with ETV6::RUNX1 positivity or hyperdiploidy, after MRD-guided risk stratification and treatment intensification enabled intermediate-risk patients to achieve survival rates comparable to those of low-risk patients. Conversely, in NENH-B-ALL, although MRD effectively stratified patients into low, intermediate and high-risk groups, treatment adjustments failed to eliminate the prognostic disparities. 目的: 评估微小残留病(MRD)指导的危险度分层对B细胞型急性淋巴细胞白血病(B-ALL)不同亚型患儿临床治疗的价值。 方法: 回顾性队列研究。纳入浙江大学医学院附属儿童医院2018年10月至2023年6月666例初诊B-ALL患儿,采用浙江大学医学院附属儿童医院急性淋巴细胞白血病(ZJCH-ALL)-2019方案进行危险度分层(低危、中危、高危)并治疗。本研究根据白血病细胞遗传学和分子生物学特征将患儿分为ETV6::RUNX1融合基因阳性、超二倍体及非ETV6::RUNX1且非超二倍体B-ALL(NENH-B-ALL)3组,分析各组患儿根据MRD调整危险度的情况,并用Kaplan-Meier生存分析法和Cox比例风险模型评估基于MRD水平的危险度调整策略在不同亚组的B-ALL患儿中的价值。 结果: 666例患儿中男379例、女287例,发病年龄4.7(3.2,7.6)岁。ETV6::RUNX1融合基因阳性组、超二倍体组及NENH-B-ALL组的患儿分别有168例(25.2%)、199例(29.9%)和293例(44.0%),另有6例患儿为超二倍体合并ETV6::RUNX1融合基因阳性。分别有153例(23.0%)患儿和5例(0.8%)患儿根据第15天和第29天的MRD水平进行了危险度调整。666例患儿的5年总生存率(OS)和无事件生存率(EFS)分别为(95.9±0.8)%和(92.1±1.2)%,其中ETV6::RUNX1融合基因阳性和超二倍体患儿EFS优于NENH-B-ALL患儿[(97.6±1.2)%、(96.5±1.4)%比(85.6±2.4)%,P<0.001]。ETV6::RUNX1融合基因阳性患儿低危组、中危组和高危组的5年EFS分别为100%、(98.5±1.5)%和(80.0±10.7)%;超二倍体患儿低危组、中危组和高危组的5年EFS分别为(96.7±1.9)%、100%和(87.7±6.7)%;而NENH-B-ALL患儿低危组、中危组和高危组的5年EFS分别为(97.2±1.9)%、(85.8±3.6)%和(74.4±5.4)%,差异均有统计学意义(均P<0.001)。年龄≥10岁(HR=3.37,95%CI 1.81~6.27)、初诊白细胞计数≥50×109/L(HR=2.31,95%CI 1.24~4.32)、第15天MRD≥0.1%(HR=1.88,95%CI 1.01~3.49)、第29天MRD≥0.01%(HR=2.72,95%CI 1.19~6.21)及NENH-B-ALL(HR=1.66,95%CI 1.16~2.39)均是独立的不良预后因素(均P<0.05)。 结论: ETV6::RUNX1融合基因阳性和超二倍体患儿中,依据MRD调整危险度和治疗强度后,中低危组患儿生存率均较高;而在NENH-B-ALL中,MRD虽可有效划分低、中、高3个风险层次,但治疗强度调整仍难以改变预后差异。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Liang J, Xu XJ, Xu WQ, et al. [The value of minimal residual disease-guided risk stratification in different subtypes of pediatric B-cell acute lymphoblastic leukemia]. Zhonghua Er Ke Za Zhi. 2026. PMID: 41986264. doi:10.3760/cma.j.cn112140-20260317-00214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。